These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 22226053)

  • 21. Glucagon-Like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight.
    Anderberg RH; Richard JE; Eerola K; López-Ferreras L; Banke E; Hansson C; Nissbrandt H; Berqquist F; Gribble FM; Reimann F; Wernstedt Asterholm I; Lamy CM; Skibicka KP
    Diabetes; 2017 Apr; 66(4):1062-1073. PubMed ID: 28057699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats.
    Hansen G; Jelsing J; Vrang N
    Acta Pharmacol Sin; 2012 Feb; 33(2):194-200. PubMed ID: 22301859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.
    González C; Beruto V; Keller G; Santoro S; Di Girolamo G
    Expert Opin Investig Drugs; 2006 Aug; 15(8):887-95. PubMed ID: 16859392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.
    Irwin N; Flatt PR; Patterson S; Green BD
    Eur J Pharmacol; 2010 Feb; 628(1-3):268-73. PubMed ID: 19917278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
    Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide to Characterize Its Antiobesity Effects in Diet-Induced Obese Mice.
    Iwasaki S; Hamada T; Chisaki I; Andou T; Sano N; Furuta A; Amano N
    J Pharmacol Exp Ther; 2017 Sep; 362(3):441-449. PubMed ID: 28698254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice.
    Li Y; Bader M; Tamargo I; Rubovitch V; Tweedie D; Pick CG; Greig NH
    J Neurochem; 2015 Dec; 135(6):1203-1217. PubMed ID: 25982185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats.
    Chelikani PK; Haver AC; Reidelberger RD
    Am J Physiol Regul Integr Comp Physiol; 2005 Jun; 288(6):R1695-706. PubMed ID: 15718384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity.
    Maselli DB; Camilleri M
    Adv Exp Med Biol; 2021; 1307():171-192. PubMed ID: 32077010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
    Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
    Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GLP-1 receptor agonists have a sustained stimulatory effect on corticosterone release after chronic treatment.
    Krass M; Volke A; Rünkorg K; Wegener G; Lund S; Abildgaard A; Vasar E; Volke V
    Acta Neuropsychiatr; 2015 Feb; 27(1):25-32. PubMed ID: 25469828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
    Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
    J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2007 Apr; 62(4):217-21. PubMed ID: 17566392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon-like peptide-1 regulation of carbohydrate intake is differentially affected by obesogenic diets.
    Pritchett CE; Hajnal A
    Obesity (Silver Spring); 2012 Feb; 20(2):313-7. PubMed ID: 22134200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
    Secher A; Jelsing J; Baquero AF; Hecksher-Sørensen J; Cowley MA; Dalbøge LS; Hansen G; Grove KL; Pyke C; Raun K; Schäffer L; Tang-Christensen M; Verma S; Witgen BM; Vrang N; Bjerre Knudsen L
    J Clin Invest; 2014 Oct; 124(10):4473-88. PubMed ID: 25202980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Glucagon-like peptide-1 analogues: effects on body weight and glycemia].
    Ruffo M; Hribal ML; Sesti G
    G Ital Cardiol (Rome); 2010 Dec; 11(12 Suppl 2):12S-17S. PubMed ID: 21361051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer.
    Chiu WY; Shih SR; Tseng CH
    Exp Diabetes Res; 2012; 2012():924168. PubMed ID: 22693487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.
    Sauer N; Reining F; Schulze Zur Wiesch C; Burkhardt T; Aberle J
    Horm Metab Res; 2015 Jul; 47(8):560-4. PubMed ID: 25230325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure.
    Bagger JI; Holst JJ; Hartmann B; Andersen B; Knop FK; Vilsbøll T
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4541-52. PubMed ID: 26445112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.